An efficacy and safety evaluation of Nasacort AQ 110 microg QD in children aged 2-5 years with perennial allergic rhinitis.

Trial Profile

An efficacy and safety evaluation of Nasacort AQ 110 microg QD in children aged 2-5 years with perennial allergic rhinitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2011

At a glance

  • Drugs Triamcinolone (Primary)
  • Indications Perennial allergic rhinitis; Seasonal allergic rhinitis
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 01 Apr 2009 Results reported in the Annals of Allergy, Asthma & Immunology 2009.
    • 23 Sep 2008 Sanofi-aventis annouces FDA approval of triamcinolone nasal spray [Nasacort AQ Nasal Spray] in children aged 2-5 years based on the results of this trial.
    • 18 Mar 2008 Results reported at AAAAI.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top